David Cordúa, right, leads The Lymbar. Photo by Dylan McEwan

A veteran Houston chef’s new Midtown bar and restaurant is taking shape. When it opens later this fall, The Lymbar will mark chef David Cordúa’s return to Houston's dining scene.

Cordúa's name is well known to Houston diners. The chef worked with his father, legendary Houston restaurateur Michael Cordúa, at Cordúa Restaurants — the hospitality group behind Churrascos, Americas, and Amazon Grill — before the duo parted ways with the company in 2018. They're teaming up again on this new project.

Located inside The Ion, Rice University’s innovation district in the former Sears in Midtown, The Lymbar describes itself as an all-day neighborhood craft cocktail bar and restaurant. Named for the street in Meyerland where Cordúa grew up, the restaurant will serve an eclectic menu of Latin and Mediterranean-inspired dishes in a space designed by local firm Gin Design Group (Eunice, Daily Gather).

“The Ion already has an exciting buzz of ‘greenergy’ with great minds, start-ups and entrepreneurs coming together. The Lymbar will be their living room,” Cordúa said in a statement. “The vibe is ‘Golden Girls Chic’ with inspiration from childhood nostalgia like ‘Where the Wild Things Are’ and Shel Silverstein.”

Cordúa provided CultureMap with a preview of some of the menu items he plans to serve at The Lymbar. Those looking for a bar snack may order the 'Rosespud', oversized potato and plantain chips served with dips such as onion dip, chimichurri, and red curry romesco or items such as foie gras doughnut holes, Monte Cristo empanadas with raspberry dill vinaigrette, and sweet corn flan with Cracker Jacks. The truffle twinkie that won him the top prize at the first Truffle Masters competition will also be available.

Meals will begin with seasonal small plates such as fresh corn gnocchi with smoked tomato sauce, labneh and basil as well as rotating flatbreads like caramelized onions with new potatoes. Entree options include a stuffed chicken ballotine with sherry cream sauce and morels that draws upon the chef’s French training or go South American with a dish like arroz tumbado with oven-roasted branzino.

Expect to see The Lymbar’s build-your-own-taco boards on Instagram. They’ll combine proteins such as chicken shawarma, achiote pork belly, and sesame-seasoned tri-tip with basmati rice and house sourdough pita.

The chef has recruited an experienced group to help him open the restaurant. They include: executive chef Adolfo Lopez, Jr. (Brenner’s on the Bayou, Churrascos); general manager Jaime Rangel (Cordúa Restaurants); manager Travis Wingate (Churrascos, La Griglia); and bar manager Sean Stapleton (The Refuge in the Woodlands).

“We’re the lobby bar of The Ion,” Cordúa added. “We’ll be a place that celebrates the creativity and innovative spirit that makes Houston one of the best cities in the world.”

Already home to a location of Common Bond On-The-Go and Second Draught, a craft beer bar, The Ion will also soon welcome Late August, a Afro-Asian restaurant from Houston chef and Top Chef finalist Dawn Burrell.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”